223 related articles for article (PubMed ID: 26076815)
21. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
Soh SX; Siddiqui FJ; Allen JC; Kim GW; Lee JC; Yatabe Y; Soda M; Mano H; Soo RA; Chin TM; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee JH; Yang JC; Zhao M; Zhou C; Lee JK; Lee SH; Lee JY; Ahn MJ; Tan TJ; Tan DS; Tan EH; Ong ST; Lim WT
Oncotarget; 2017 Jun; 8(25):41474-41486. PubMed ID: 28467813
[TBL] [Abstract][Full Text] [Related]
22. [Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor].
Zheng L; Lin B; Song Z; Xie F; Hong W; Feng J; Shao L; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):632-8. PubMed ID: 24345487
[TBL] [Abstract][Full Text] [Related]
23. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.
Zou Q; Zhan P; Lv T; Song Y
Transl Lung Cancer Res; 2015 Dec; 4(6):792-6. PubMed ID: 26798589
[TBL] [Abstract][Full Text] [Related]
24. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.
Isobe K; Hata Y; Tochigi N; Kaburaki K; Kobayashi H; Makino T; Otsuka H; Sato F; Ishida F; Kikuchi N; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Iyoda A; Homma S
J Thorac Oncol; 2014 Apr; 9(4):483-7. PubMed ID: 24736070
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
[TBL] [Abstract][Full Text] [Related]
27. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
Katagiri S; Umezu T; Ohyashiki JH; Ohyashiki K
Br J Haematol; 2013 Jan; 160(2):269-71. PubMed ID: 23116058
[No Abstract] [Full Text] [Related]
28. The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
Rauzan M; Chuah CT; Ko TK; Ong ST
PLoS One; 2017; 12(3):e0174107. PubMed ID: 28301600
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.
Gillings AS; Balmanno K; Wiggins CM; Johnson M; Cook SJ
FEBS J; 2009 Nov; 276(21):6050-62. PubMed ID: 19788418
[TBL] [Abstract][Full Text] [Related]
30. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
Incharoen P; Charonpongsuntorn C; Saowapa S; Sirachainan E; Dejthevaporn T; Kampreasart K; Trachu N; Muntham D; Reungwetwattana T
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3581-3589. PubMed ID: 31870097
[TBL] [Abstract][Full Text] [Related]
31. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
Wu DW; Chen CY; Chu CL; Lee H
Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
[TBL] [Abstract][Full Text] [Related]
32. In cancer drug resistance, germline matters too.
Cheng EH; Sawyers CL
Nat Med; 2012 Apr; 18(4):494-6. PubMed ID: 22481406
[No Abstract] [Full Text] [Related]
33. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
34. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.
Yuan J; Li B; Zhang N; Zhu H; Zhou L; Zhang L; Yang M
Clin Lung Cancer; 2018 Jul; 19(4):e431-e438. PubMed ID: 29580739
[TBL] [Abstract][Full Text] [Related]
37. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
38. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
[TBL] [Abstract][Full Text] [Related]
39. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Takeuchi S; Hase T; Shimizu S; Ando M; Hata A; Murakami H; Kawakami T; Nagase K; Yoshimura K; Fujiwara T; Tanimoto A; Nishiyama A; Arai S; Fukuda K; Katakami N; Takahashi T; Hasegawa Y; Ko TK; Ong ST; Yano S
Cancer Sci; 2020 Feb; 111(2):561-570. PubMed ID: 31782583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
